Patents
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
02/2006
02/02/2006WO2005085861A3 Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer
02/02/2006WO2005067543A3 Murine calicivirus
02/02/2006WO2005066207A8 Glucagon-like peptide-1 analogs with long duration of action
02/02/2006WO2005051996A3 Protein from horn fly saliva that disrupts hemostasis
02/02/2006WO2005046577A3 Human prostaglandin ep1 receptor variants and methods of using same
02/02/2006WO2005016130A3 Recombinant lubricin molecules and uses thereof
02/02/2006WO2004113503A3 Mbms as modifiers of branching morphogenesis and methods of use
02/02/2006WO2004100877A3 Vaccine accelerator factor (vaf) for poultry
02/02/2006WO2003102166A3 Novel flavivirus antigens
02/02/2006WO2003093298A3 Immunogenic peptides
02/02/2006WO2003035006A3 Amyloid ss is a ligand for fpr class receptors
02/02/2006WO2002101071A3 Cd43:modulators of mast cell degranulation
02/02/2006WO2002094990A3 Receptors and membrane-associated proteins
02/02/2006US20060026720 Plant proteins
02/02/2006US20060026719 Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
02/02/2006US20060026716 Transcriptional activators involved in abiotic stress tolerance
02/02/2006US20060026707 Isolated from Zea mays; transformed plant; can be used to repress the expression of a desired target gene in specific plant tissue or to prevent the repression of a particular desired target gene
02/02/2006US20060026701 Human albumin animal models for drug evaluation, Toxicology and immunogenicity studies
02/02/2006US20060026700 Tissue specific genes and gene clusters
02/02/2006US20060026698 Transgenic transchromosomal rodents for making human antibodies
02/02/2006US20060025582 Promoter sequences for corticotropin releasing-factor receptor CRF2alpha and method of identifying agents that alter the activity of the promoter sequences
02/02/2006US20060025581 Novel human GABA receptor proteins and polynucleotides encoding the same
02/02/2006US20060025580 Novel human estrogen receptor beta
02/02/2006US20060025578 Chemical synthesis of reagents for peptide coupling
02/02/2006US20060025577 Endothelial cell growth factor methods of isolation and expression
02/02/2006US20060025575 Hybridoma cell line producing monoclonal antibodies to bind to, to detect and qualitatively and quantitatively measure the presence of epitopes of prion proteins; neurodegenerative diseases of the central nervous system
02/02/2006US20060025574 32 human secreted proteins
02/02/2006US20060025573 Reducing the immunogenicity of fusion proteins
02/02/2006US20060025572 Mammalian cell surface antigens; related reagents
02/02/2006US20060025571 Morphogen-induced dendritic growth
02/02/2006US20060025570 Megakaryocyte stimulating factors
02/02/2006US20060025565 purified polypeptide and fusion protein for promoting the survival, growth, proliferation, or maintenance of neurons in an injured but not severed spinal cord; axonal regeneration, side effect reduction of scar tissue formation
02/02/2006US20060025397 Method of resistance of epilepsy by suppressing the function of alpha 1g protein
02/02/2006US20060025367 Adenovirus vectors encoding brain natriuretic peptide
02/02/2006US20060025362 Guanylate binding protein (GBP-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation
02/02/2006US20060025360 Human cervical cancer protooncogene and protein encoded therein
02/02/2006US20060025348 Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
02/02/2006US20060025344 Ghrelin receptor inverse agonists for regulation of feeding behaviors
02/02/2006US20060025343 Angiogenically effective unit dose fo FGF and method of adminstering
02/02/2006US20060025341 Isolated polynucleotide encoding inhibin-related proteins for treating cancer of epithelial, testicular, ovarian, prostate; biodrug protein; activin binding activity; hormone inhibitor; muscle regeneration
02/02/2006US20060025339 Corticotropin releasing factor 2 receptor agonists
02/02/2006US20060025334 Vanilloid receptor-2 ligands for treating anxiety or depression
02/02/2006US20060025327 Hybrid molecules QA, wherein Q is an aminoquinoline and a is an antibiotic or a resistance enzyme inhibitor, their synthesis and their uses as antibacterial agent
02/02/2006US20060024830 Growth characteristics of filamentous microorganisms
02/02/2006US20060024821 Rolling circle replicon expression vector
02/02/2006US20060024820 Chromosome-based platforms
02/02/2006US20060024804 Isoforms isolated and purified from mammalian colostrum
02/02/2006US20060024798 Gene knockout; gene overexpression; liposomes
02/02/2006US20060024797 Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes
02/02/2006US20060024796 Transcriptional activator gene for genes involved in cobalamin biosynthesis
02/02/2006US20060024795 Interferon-Like molecules and uses thereof
02/02/2006US20060024794 Novel methods for production of di-chain botulinum toxin
02/02/2006US20060024792 G-protein coupled receptors
02/02/2006US20060024790 Recombinant cage-like protein, method for producing the same, precious metal-recombinant cage-like protein complex, method for producing the same and recombinant DNA
02/02/2006US20060024788 Inducible alphaviral gene expression system
02/02/2006US20060024787 Chimp trace amine associated receptors and polypeptides
02/02/2006US20060024785 Having mutations in the Kinase domain region (KDR) and/or the FMS-like Tyrosine-Kinase region (FLT-1), said variants exhibiting modified binding characteristics at said regions compared with native VEGF; stimulates vasculogenesis or angiogenesis; wound healing
02/02/2006US20060024783 BMP10 propeptides and related methods
02/02/2006US20060024780 Isolation; cloning; hybrid anticancer agents; protein genetic mapping of human chromosome
02/02/2006US20060024779 Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
02/02/2006US20060024778 Method for enzymatic production of GLP-2(1-33) and GLP-2(1-34) peptides
02/02/2006US20060024777 preparation of non-bitter protein hydrolyzate with defined degree of hydrolysis of 30-33% and an arginine:lysine ratio of at least 5.5:1 from groundnut protein isolate, especially using fungal protease from Aspergillus
02/02/2006US20060024766 Bifunctional molecules
02/02/2006US20060024761 Protein biopolymer markers predictive of alzheimer's disease
02/02/2006US20060024760 Human brain carboxypeptidase B
02/02/2006US20060024759 Complex of a chaperone with beta-amyloid and methods employing this complex
02/02/2006US20060024754 Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
02/02/2006US20060024750 identification of the natural ligand for the orphan G-Protein Coupled Receptor; diagnosis of conditions involving dysregulated receptor activity
02/02/2006US20060024748 Cytoxan antibodies and immunoassay
02/02/2006US20060024747 Comprises nucleotide sequences coding nitrillase and amidase for transformation and propagation of microorganism capable of catalyzing hydration of certain nitrites to corresponding amides and amides to corresponding carboxylic acids
02/02/2006US20060024743 Probes labeled with energy transfer coupled dyes
02/02/2006US20060024742 Immunogenic polypeptide of given sequence; diagnosis or treatment of conditions resulting from gene over-expression
02/02/2006US20060024739 C. elegans gro-1 gene
02/02/2006US20060024730 TF binding compounds
02/02/2006US20060024729 Mechanosensitive mammalian potassium channels activatable by polyunsaturated fatty acids and the use of said channels in drug screening
02/02/2006US20060024726 Position dependent recognition of GNN nucleotide triplets by zinc fingers
02/02/2006US20060024706 Transforming growth factor beta 1 (TGFbeta1) haplotypes and prediction of susceptibility for immunological disorders
02/02/2006US20060024700 determining whether a hepatitis C virus-infected human has an increased risk for developing liver fibrosis, comprising testing nucleic acid from the human for a polymorphism in gene TLR4 as represented by position 101 of SEQ ID NO: 18973 or its complement
02/02/2006US20060024696 Nucleic acid and polypeptide sequences from Lawsonia intracellularis and methods of using
02/02/2006US20060024689 Process for the purification of recombinant proteins from complex media and purified proteins obtained thereby
02/02/2006US20060024688 Alterations of fibulin genes in macular degeneration
02/02/2006US20060024683 Transcription factor of MHC class II genes, substances capable of inhibiting this transcription factor and medical uses of these substances
02/02/2006US20060024670 Influenza virus vaccine composition and methods of use
02/02/2006US20060024668 Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
02/02/2006US20060024332 Recombinant ESAT-6:CFP-10 fusion protein useful for specific diagnosis of tuberculosis
02/02/2006US20060024331 Toxin compounds with enhanced membrane translocation characteristics
02/02/2006US20060024329 Recombinant live vaccine based on canine herpesvirus, in particular against Carre's disease, rabies or the parainfluenza virus type 2.
02/02/2006US20060024324 Glutamate-rich protein (GLURP) genetically coupled to plasmodium falciparum merozoite surface protein 3 (MSP3) for use as tool in preventing malarial infection; Antimalarial agents; parasiticides
02/02/2006US20060024323 Active immunization using a siderophore receptor protein
02/02/2006US20060024322 Novel prophylactics/remedies for immunopathy
02/02/2006US20060024321 chemokines; open reading frames; long terminal repeats; site directed mutagenesis; antibodies
02/02/2006US20060024320 Attenuated pestiviruses
02/02/2006US20060024319 determining whether a mouse is infected with murine norovirus-1 by determining presence, absence or quantity of antibody against MNV-1 a sample of a mouse; the antibody binds to MNV-1 deposited as American Type Culture Collection (ATCC) Deposit No. PTA-5935 or to a polypeptide encoded by it
02/02/2006US20060024316 Prostatic cancer vaccine
02/02/2006US20060024310 Methods of treating TNFalpha-mediated tissue injury using anti-TNF antibodies and peptides
02/02/2006US20060024305 Camp-regulated phosphoprotein for diagnostic and therapeutic use in neurodegenerative diseases
02/02/2006US20060024301 Prostate-specific polypeptides and fusion polypeptides thereof
02/02/2006US20060024299 Human osteoclast derived cathepsin
02/02/2006US20060024296 As an antagonist that inhibits immunoglobulin secretion; autoimmune disorders; antiproliferative , anticarcinogenic and antiarthritic agents; inflammatory bowel disease
02/02/2006US20060024291 Protocadherin materials and methods